Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
The metabolic adaptations that defend higher body weight return when medication support ends
In the SURMOUNT-4 trial published in the New England Journal of Medicine, participants who switched from tirzepatide to placebo regained approximately two-thirds of their lost weight over the subsequent 52 weeks, while those continuing treatment maintained their weight loss and achieved additional reductions
The adjusted mean total body weight change in the semaglutide group was 21.1 kg (s.e
Additionally, GLP-1 drugs have been shown to lower the risk of major cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes, regardless of their impact on blood sugar levels
